Literature DB >> 33318004

The Pharmacodynamic-Toxicodynamic Relationship of AUC and C max in Vancomycin-Induced Kidney Injury in an Animal Model.

Sean N Avedissian1,2, Gwendolyn Pais3,4, Jiajun Liu3,4, J Nicholas O'Donnell5, Thomas P Lodise5, Michael Neely6, Walter C Prozialeck7, Peter C Lamar7, Leighton Becher3, Marc H Scheetz8,4,7.   

Abstract

Vancomycin induces exposure-related acute kidney injury. However, the pharmacokinetic-toxicodynamic (PK-TD) relationship remains unclear. Sprague-Dawley rats received intravenous (i.v.) vancomycin doses of 300 mg/kg/day and 400 mg/kg/day, divided into once-, twice-, three-times-, or four-times-daily doses (i.e., QD, BID, TID, or QID) over 24 h. Up to 8 samples plus a terminal sample were drawn during the 24-h dosing period. Twenty-four-hour urine was collected and assayed for kidney injury molecule-1 (KIM-1). Vancomycin was quantified via liquid chromatography-tandem mass spectrometry (LC-MS/MS). Following terminal sampling, nephrectomy and histopathologic analyses were conducted. PK analyses were conducted using Pmetrics. PK exposures (i.e., area under the concentration-time curve from 0 to 24 h [AUC0-24] and maximum concentration from 0 to 24 h [C max0-24]) were calculated for each rat, and PK-TD relationships were discerned. A total of 53-rats generated PK-TD data. A 2-compartment model fit the data well (Bayesian observed versus predicted concentrations; R 2 = 0.96). KIM-1 values were greater in QD and BID groups (P for QD versus TID, <0.002; P for QD versus QID, <0.004; P for BID versus TID, <0.002; and P for BID versus QID, <0.004). Exposure-response relationships were observed between KIM-1 versus C max0-24 and AUC0-24 (R 2 = 0.7 and 0.68). Corrected Akaike's information criterion showed C max0-24 as the most predictive PK-TD driver for vancomycin-induced kidney injury (VIKI) (-5.28 versus -1.95). While PK-TD indices are often intercorrelated, maximal concentrations and fewer doses (for the same total daily amount) resulted in increased VIKI in our rat model.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  pharmacodynamics; pharmacokinetics; pharmacology; rat; toxicodynamics; vancomycin

Mesh:

Substances:

Year:  2021        PMID: 33318004      PMCID: PMC8092494          DOI: 10.1128/AAC.01945-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Pharmacokinetics of centhaquin citrate in a dog model.

Authors:  J Nicholas O'Donnell; E Paul O'Donnell; E Jeevan Kumar; Manish S Lavhale; Shridhar V Andurkar; Anil Gulati; Marc H Scheetz
Journal:  J Pharm Pharmacol       Date:  2016-04-25       Impact factor: 3.765

2.  Vancomycin: The pendulum swings.

Authors:  Marc H Scheetz
Journal:  Am J Health Syst Pharm       Date:  2020-05-19       Impact factor: 2.637

3.  Continuous Versus Intermittent Infusion of Vancomycin and the Risk of Acute Kidney Injury in Critically Ill Adults: A Systematic Review and Meta-Analysis.

Authors:  Alexander H Flannery; Brittany D Bissell; Melissa Thompson Bastin; Peter E Morris; Javier A Neyra
Journal:  Crit Care Med       Date:  2020-06       Impact factor: 7.598

Review 4.  Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy.

Authors:  Annie Wong-Beringer; Julianne Joo; Edmund Tse; Paul Beringer
Journal:  Int J Antimicrob Agents       Date:  2010-12-03       Impact factor: 5.283

5.  Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study.

Authors:  M Wysocki; F Delatour; F Faurisson; A Rauss; Y Pean; B Misset; F Thomas; J F Timsit; T Similowski; H Mentec; L Mier; D Dreyfuss
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury.

Authors:  Gwendolyn M Pais; Sean N Avedissian; J Nicholas O'Donnell; Nathaniel J Rhodes; Thomas P Lodise; Walter C Prozialeck; Peter C Lamar; Cameron Cluff; Anil Gulati; Julie C Fitzgerald; Kevin J Downes; Athena F Zuppa; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 7.  Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis.

Authors:  Jing-Jing Hao; Han Chen; Jian-Xin Zhou
Journal:  Int J Antimicrob Agents       Date:  2015-11-24       Impact factor: 5.283

8.  Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.

Authors:  Vishal S Vaidya; Josef S Ozer; Frank Dieterle; Fitz B Collings; Victoria Ramirez; Sean Troth; Nagaraja Muniappa; Douglas Thudium; David Gerhold; Daniel J Holder; Norma A Bobadilla; Estelle Marrer; Elias Perentes; André Cordier; Jacky Vonderscher; Gérard Maurer; Peter L Goering; Frank D Sistare; Joseph V Bonventre
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

9.  Preclinical evaluation of novel urinary biomarkers of cadmium nephrotoxicity.

Authors:  Walter C Prozialeck; Joshua R Edwards; Vishal S Vaidya; Joseph V Bonventre
Journal:  Toxicol Appl Pharmacol       Date:  2009-02-06       Impact factor: 4.219

10.  Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.

Authors:  Tatiana Tatarinova; Michael Neely; Jay Bartroff; Michael van Guilder; Walter Yamada; David Bayard; Roger Jelliffe; Robert Leary; Alyona Chubatiuk; Alan Schumitzky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-13       Impact factor: 2.745

View more
  3 in total

1.  Vancomycin Pharmacokinetics in a Pregnancy Rat Model.

Authors:  Sean N Avedissian; Gwendolyn M Pais; Michelle Pham; Jiajun Liu; Jack Chang; Khrystyna Hlukhenka; Walter Prozialeck; Brooke Griffin; Anil Gulati; Medha D Joshi; Ying Mu; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2022-04-21       Impact factor: 5.938

2.  Of Rats and Men: a Translational Model To Understand Vancomycin Pharmacokinetic/Toxicodynamic Relationships.

Authors:  Marc H Scheetz; Gwendolyn M Pais; Thomas P Lodise; Steven Y C Tong; Joshua S Davis; J Nicholas O'Donnell; Jiajun Liu; Michael Neely; Walter C Prozialeck; Peter C Lamar; Nathaniel J Rhodes; Thomas Holland; Sean N Avedissian
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191

3.  Precision dosing of vancomycin: in defence of AUC-guided therapy in children.

Authors:  Mark E Murphy; Sonya Tang Girdwood; Jennifer L Goldman; Marc H Scheetz; Kevin J Downes
Journal:  J Antimicrob Chemother       Date:  2021-09-15       Impact factor: 5.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.